

AD HOC Announcement According to §15 WpHG

Qiagen N.V.:

QIAGEN makes organizational and leadership changes

Venlo, The Netherlands, April 25, 2012 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it was making organizational changes designed to capture opportunities and further improve its capabilities to address the needs of its customers.

Two new Business Areas – Molecular Diagnostics and Life Sciences – will be created as of July 1 under the leadership of new Executive Committee (EC) members. Dr. Helge Lubenow, who has been with QIAGEN since 1997 and currently serves as Vice President, Molecular Diagnostics Marketing, has been appointed Senior Vice President, Molecular Diagnostics Business Area, and a member of the EC. Dr. Dietrich Hauffe, who has been with QIAGEN since 2010 (also from 1997-2000) and currently serves as Vice President, Life Sciences Marketing, has been appointed Senior Vice President, Life Sciences Business Area, and a member of the EC.

Dr. Joachim Schorr, Managing Director, Senior Vice President Global Research and Development, has decided to leave the company but has been retained as a consultant. The responsibilities of Dr. Schorr, who will leave QIAGEN during the second quarter of 2012, will be assumed by the R&D leaders of the Business Areas.

QIAGEN's Executive Committee will now be comprised of the following members: Peer M. Schatz (CEO); Dietrich Hauffe (Life Sciences Business Area, new); Douglas Liu (Operations); Helge Lubenow (Molecular Diagnostics Business Area, new); Roland Sackers (CFO); Ulrich Schriek (Business Development); Thomas Schweins (Human Resources, Corporate Strategy and Marketing Services); and Bernd Uder (Commercial Operations).

Contacts QIAGEN N.V.:

Investor Relations

John Gilardi, Tel: +49 2103 29 11711; ir@qiagen.com

Public Relations

Dr. Thomas Theuringer, Tel: +49 2103 29 11826; pr@qiagen.com